The blockade of the PD-1/PD-L1 pathway (Figure 2) has transformed immunotherapy with a promising increase in OS rates, leading to U.S. Food and Drug Administration (FDA) approval of these immune checkpoint blockade drugs for the treatment of a broad range of tumour types over the past decade. This evidence concerns the gene CD274 and neoplasm.